Antisense therapy: Current status in prostate cancer and other malignancies

Cancer and Metastasis Reviews

Volumn 21, Issue 1, 2002, Pages 79-92

  Gleave, Martin ^a   Miyake, Hideake ^a   Zangemeister Wittke, Uwe ^b   Jansen, Burkhard ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antisense therapy; ASOs; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CGP 69846A; CLUSTERIN; DOCETAXEL; GENE EXPRESSION MODULATOR 231; GTI 2040; INHIBITOR OF APOPTOSIS PROTEIN; INX 3001; ISIS 2503; ISIS 3521; MESSENGER RNA; METHYLPHOSPHONIC ACID; MG 98; MITOXANTRONE; OBLIMERSEN; OGX 011; PACLITAXEL; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; SOMATOMEDIN BINDING PROTEIN; SUGAR; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER; CLINICAL TRIAL; DNA HYBRIDIZATION; DNA MODIFICATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG STABILITY; EVIDENCE BASED MEDICINE; FATIGUE; GENE TARGETING; HEART DISEASE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MYALGIA; NEUTROPENIA; NONHUMAN; ONCOGENE H RAS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RNA CLEAVAGE; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH;

APOPTOSIS; CLUSTERIN; GENES, BCL-2; GLYCOPROTEINS; HUMANS; MALE; MOLECULAR CHAPERONES; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0036405323     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020172424152     Document Type: Review

References (105)

1. Belikova AM ZVGN: Synthesis of ribonucleosides and diribonucleosides phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett 37: 3357-3362, 1967
2. Paterson BM, Roberts BE, Kuff EL: Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74: 4370-4374, 1977
3. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284, 1978
4. Donis-Keller H: Site specific enzymatic cleavage of RNA 2. Nucleic Acids Res 7: 179-192, 1979
5. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expressio. J Biol Chem 268: 14514-14522, 1993
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001
7. Bacon TA, Wickstrom E: Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region. Oncogene Res 6: 13-19, 1991
8. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2: 668-675, 1996
9. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Nat Cancer Inst 89: 1027-1036, 1997
10. Milner N, Mir KU, Southern EM: Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 15: 537-541, 1997
11. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 16: 59-63, 1998
12. Mathews DH, Sabina J, Zuker M, Turner DH: Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 288: 911-940, 1999
13. Crooke ST: Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Development 8: 133-134, 1998
14. Galderisi U, Cascino A, Giordano A: Antisense oligonucleotides as therapeutic agents 4. J Cell Physiol 181: 251-257, 1999
15. Agrawal S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1489: 53-68, 1999
16. Krieg AM, Yi AK, Hartmann G: Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol Ther 84: 113-120, 1999
17. Altmann KH, Dean NM, Fabbro D, Freier SM, Geiger T, Haener R, Huesken D, Martin P, Monia BP, Mueller M, Natt F, Nicklin P, Phillips J, Pieles U, Sasmor H, Moser HE: Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia 50: 168-176, 1996
18. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, Broberger C, Porreca F, Lai J, Ren K, Ossipov M, Koshkin A, Jakobsen N, Skouv J, Oerum H, Jacobsen MH, Wengel J: Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638, 2000
19. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik ES, Sasmor HM, Bennett CF: 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272: 11994-12000, 1997
20. McKay RA, Miraglia LJ, Cummins LL, Owens RS, Sasmor H, Dean NM: Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem 274: 1715-1722, 1999
21. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000
22. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322-1326, 1998
23. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71. 1992
24. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14-23, 2001
25. Isaacs JT, Wake N, Coffey DS, Sandberg AA: Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res 42:6; 2353, 1982
26. Miyake H, Tolcher A, Gleave ME: Antisense Bcl-2 oligodeoxynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Cancer Res 59: 4030-4034, 1999
27. Miyake H, Rennie P, Nelson C, Gleave ME, Miyake H, Rennie P, Nelson C, Gleave ME: Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models. Cancer Res 60: 170-176, 2000
28. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282, 1990
29. Miyake H, Nelson C, Rennie P, Gleave ME: Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141: 2257-2265, 2000
30. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the Human Prostate Cancer Cell Line LNCaP. J Bio Chem 272(28): 17485-17494, 1997
31. Craft N, Shostak Y, Carey M, Sawyers C: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5: 280-285, 1999
32. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C: Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77(6): 855-861, 1998
33. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL: Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19: 5143-5154, 1999
34. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 60: 1220-1229, 1998
35. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-3163, 1997
36. Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967, 1999
37. Smith DC, Esper D, Strawderman M, Redman B, Pienta KJ: Phase II trial of oral estramustine, oral etopside, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17: 1664-1671, 1999
38. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986
39. Sato T, Hanada M, Bodnig S, Ine S, Iwana N, Boise LH, Thompson C, Golemia E, Fong L, Wang H-G, Reed JC: Interactions among members of the bcl-2 protein family analysed with a yeast two-hybrid systems. Proc Nat Ass Sci USA 91: 9238-9242, 1994
40. McDonnell TJ, Troncoso P, Brisby SM, Logothetis CL, Chung LWK, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992
41. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993
42. Raffo AJ, Periman H, Chen MW, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445.29, 1995
43. Patterson R, Gleave M, Jone E, Zubovits J, Goldenberg SL, Sullivan LD: Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy. Mol Urol 3: 277-286, 1999
44. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 4: 232-234, 1998
45. Miyake H, Tolcher A, Gleave ME: Antisense Bcl-2 oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. JNCI 92: 34-41, 2000
46. Gleave ME, Tolcher A, Miyake H, Beraldi E, Goldie J: Progression to androgen-independence is delayed by antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clinical Cancer Res 5: 2891-2898, 1999
47. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: BCL-2 antisense therapy in patients with non-hodgkin-lymphoma. Lancet 349: 1137-1141, 1997
48. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823, 1997
49. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, DiPaola RS, Rafi M, Rosen N, Scher HI: Intravenous BCL-2 antisense alone and in combination with paclitaxel in patients with advanced cancer. Clin Cancer Res 8(3): 679-683, 2002
50. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733, 2000
51. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7(12): 3920-3927, 2001
52. Leech SH, Olie RA, Gautschi O, Simoes-Wust AP, Tschopp S, Haner R, Hall J, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 86: 570-576, 2000
53. Simoes-Wust AP, Olie RA, Gautschi O, Leech SH, Haner R, Hall J, Fabbro D, Stahel RA, Zangemeister-Wittke U: Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 87: 582-590, 2000
54. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA: Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity 1. Cancer Res 60: 6052-6060.34, 2000
55. Miyaki H, Monia B, Gleave ME: Antisense Bcl-xL and Bcl-2 Oligodeoxynucleotides synergistically enhance taxol chemosensitivity and delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Int J Cancer 86: 855-862, 2000
56. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, Nalin CM, Stahel RA: A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6: 2547-2555, 2000
57. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U: Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93: 463-471, 2001
58. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 9: 161-167, 1997
59. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 50: 236-242, 1996
60. Geiger T, Muller M, Dean NM, Fabbro D: Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13: 35-45, 1998
61. Cotter FE: Antisense oligonucleotides for haematological malignancies. Haematologica 84: 19-22, 1999
62. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI: Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5: 3357-3363, 1999
63. Alavi JB, Grossman SA Supko J: Efficacy, toxicity, and pharmacology of an antisense oligonucleotide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continous intravenous infusion in patients with recurrent high grade astrocytomas (HGA). Proc Am Soc Clin Oncol 19: 167, 2000
64. Yuen A, Advani R, Fisher G: A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. Am Soc Clin Oncol 19: 459, 2000
65. Yuen A, Halsey J, Lum B: Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC, with carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 6(Suppl): 4572, 2000
66. Koch-Brandt C, Morgans C: Clusterin: A role in cell survival in the face of apoptosis? Prog Mol Subcell Biol 16: 130-149, 1996 (review)
67. Wilson MR, Easterbrook-Smith SB: Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25: 95-98, 2000
68. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50(3): 179-188, 2000
69. Miyake H, Chi KN, Gleave ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6: 1655-1663, 2000
70. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3: 360-367, 2001
71. Miyake H, Gleave M, Kamidono S, Hara I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59(1): 150-154, 2000
72. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I: Acquisition of resistance to fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 5(3): 105-111, 2001
73. Miyake H, Rennie P, Nelson C, Gleave ME: Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2 (TRPM-2), in prostate cancer xenograft models. Cancer Res 60: 2547-2554, 2000
74. Hara I, Miyake H, Gleave ME, Kamidono S: Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 92(11): 1220-1224, 2001
75. Miyake H, Hara, I Kamidono S, Gleave ME: Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7(12): 4245-4252, 2001
76. Zellweger T, Miyake H, Monia B, Cooper S, Gleave M: Efficacy of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-o-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther 298(3): 934-940, 2001
77. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS: Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen regulated genes. Cancer Res 58: 5718-5724, 1998
78. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nature Rev 1: 34-45, 2001
79. Denis L, Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72: 3888-3895, 1993
80. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H: Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7(7): 997-1007, 2000
81. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16: 3-34, 1995
82. Nickerson T, Pollak M, Huynh H: Castration-induced apoptosis in rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology 139: 807-810, 1998
83. Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 159: 1379-1383, 1998
84. Miyake H, Pollak M, Nelson C, Gleave ME: Antisense insulin-like growth factor binding protein-5 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model via negative modulation of insulin-like growth factor-I action. Cancer Res 60: 3058-3064, 2000
85. Kiyama S, Zellweger T, Akbari M, Cox M, Miyake H, Gleave M: Antisense oligonucleotides inhibit castration-induced increases in insulin-like growth factor-binding protein-2 and delay progression to androgen-independence in the human prostate LNCaP tumor model. Eur Urol 39: 94, 2001
86. Roy N, Deveraux Q, Takahashi R, Salvesen GS, Reed JC: The c-IAP and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16: 6914-6925, 1997
87. Deveraux Q, Takahashi R, Salvesen GS, Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 17: 300-304, 1997
88. Deveraux Q, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 18: 5242-5251, 1999
89. Lacasse EC, Baird S, Korneluk RG, Mackenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998
90. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-583, 1998
91. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 3: 917-921, 1997
92. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas, Bax, and anticancer drugs. Cancer Res 58: 5315-5320, 1998
93. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, corelated with tumor cell apoptosis and p53 acculmulation in gastric carcinomas. Cancer Res 58: 1808-1812, 1998
94. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal carcinoma. Cancer Res 58: 5071-5074, 1998
95. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351: 882-883, 1998
96. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000
97. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC: Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis, and anchorage-independent growth. Neoplasia 235-241, 2000
98. Saleh M, Posey J, Pleasani L: A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 19: 320, 2000
99. Siu LL, Gelmon KA, Moore MJ: A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks. Proc Am Soc Clin Oncol 19: 250, 2000
100. de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F: BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91: 3156-3162, 1998
101. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M: Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 97: 7871-7876, 2000
102. Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79: 1956-1961, 1992
103. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F: Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res 6: 2506-2512, 2000
104. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ: Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 17: 2227-2236, 1999
105. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14: 1320-1326, 1996